| Contributors |
|
xii | (3) |
| Dedication |
|
xv | (1) |
| Preface |
|
xvi | (2) |
| Abbreviations |
|
xviii | |
|
1. History of the development of the interferons: from test-tube to patient |
|
|
1 | (18) |
|
|
|
|
|
|
|
|
1 | (1) |
|
'The antiviral penicillin' |
|
|
2 | (3) |
|
The emergence of interferon as an anticancer agent |
|
|
5 | (3) |
|
Towards a 'new' kind of cancer therapy: the interferons |
|
|
8 | (4) |
|
The interferons: retrospect and prospect |
|
|
12 | (7) |
|
2. Mechanisms of action of the interferons: biological basis |
|
|
19 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
19 | (2) |
|
Biological activities of the interferons |
|
|
21 | (6) |
|
The biological basis for side effects |
|
|
27 | (1) |
|
|
|
28 | (5) |
|
3. Mechanisms of action of the interferons: genetic and biochemical aspects |
|
|
33 | (20) |
|
|
|
|
|
|
|
|
33 | (1) |
|
Purification of human leukocyte interferon |
|
|
33 | (3) |
|
Amino acid sequences of leukocyte interferons |
|
|
36 | (1) |
|
|
|
36 | (1) |
|
Isolation of recombinants |
|
|
36 | (1) |
|
Purification of recombinant human leukocyte interferon |
|
|
37 | (2) |
|
|
|
39 | (7) |
|
|
|
46 | (7) |
|
4. Interferon in chronic viral hepatitis |
|
|
53 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
53 | (1) |
|
Chronic hepatitis B virus infection |
|
|
53 | (1) |
|
|
|
53 | (5) |
|
Hepatitis C virus infection |
|
|
58 | (5) |
|
Chronic hepatitis D virus |
|
|
63 | (1) |
|
|
|
64 | (3) |
|
5. The role of interferons in the treatment of AIDS-related Kaposi's sarcoma and HIV infection |
|
|
67 | (12) |
|
|
|
|
|
|
|
|
67 | (1) |
|
Etiology of Kaposi's sarcoma |
|
|
67 | (2) |
|
The rationale for interferon therapy |
|
|
69 | (1) |
|
Interferon-alpha for Kaposi's sarcoma |
|
|
69 | (5) |
|
|
|
74 | (1) |
|
|
|
74 | (1) |
|
|
|
74 | (5) |
|
6. Papillomatosis and condylomata acuminata |
|
|
79 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 | (1) |
|
Mechanism of interferon action specific for papillomavirus-induced disease |
|
|
80 | (2) |
|
Clinical trials of interferon in genital papillomavirus infection |
|
|
82 | (5) |
|
|
|
87 | (4) |
|
7. Interferon in the treatment of myeloproliferative disorders |
|
|
91 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
91 | (1) |
|
|
|
91 | (1) |
|
|
|
91 | (2) |
|
|
|
93 | (1) |
|
|
|
94 | (1) |
|
Chronic myelogenous leukemia |
|
|
95 | (1) |
|
|
|
95 | (1) |
|
|
|
96 | (6) |
|
|
|
102 | (1) |
|
Hypereosinophilic syndrome |
|
|
102 | (1) |
|
|
|
102 | (1) |
|
|
|
102 | (1) |
|
|
|
103 | (1) |
|
Systemic mast cell disease |
|
|
103 | (1) |
|
|
|
103 | (1) |
|
|
|
103 | (1) |
|
|
|
104 | (5) |
|
|
|
109 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
109 | (1) |
|
Mechanisms of action of the interferons in multiple myeloma |
|
|
109 | (1) |
|
Clinical studies of interferon in multiple myeloma |
|
|
110 | (9) |
|
9. Interferon in the treatment of essential thrombocythemia |
|
|
119 | (10) |
|
|
|
|
|
|
|
|
119 | (1) |
|
Open issues on the treatment of essential thrombocythemia |
|
|
120 | (1) |
|
The use of interferons in essential thrombocythemia |
|
|
121 | (1) |
|
Clinical trials with interferon-alpha in essential thrombocythemia |
|
|
122 | (3) |
|
|
|
125 | (4) |
|
10. Interferon therapy in non-Hodgkin's lymphoma and Hodgkin's disease |
|
|
129 | (14) |
|
|
|
|
|
|
|
|
129 | (1) |
|
Rationale for the use of interferon in lymphoma |
|
|
129 | (1) |
|
Early phase I or II trials of interferon in lymphoma |
|
|
130 | (1) |
|
Follicular (follicle center) lymphoma |
|
|
130 | (5) |
|
Other low grade B-cell lymphomas and chronic lymphocytic leukemia |
|
|
135 | (1) |
|
Large cell lymphomas and other aggressive lymphomas |
|
|
136 | (1) |
|
|
|
136 | (1) |
|
Cutaneous T-cell lymphomas |
|
|
136 | (1) |
|
Adjuvant therapy after high-dose therapy with autologous stem cell transplantation |
|
|
137 | (6) |
|
11. Interferon in gastrointestinal tumors: carcinoid tumors |
|
|
143 | (8) |
|
|
|
|
|
|
|
|
143 | (2) |
|
|
|
145 | (1) |
|
Combination therapy with interferon-alpha |
|
|
146 | (1) |
|
Adverse reactions to interferon-alpha |
|
|
147 | (1) |
|
Mechanisms of action of interferon-alpha in carcinoid tumors |
|
|
147 | (1) |
|
|
|
148 | (3) |
|
12. The genetics of colorectal cancer and the role of interferons: towards a rational approach to therapeutic design |
|
|
151 | (18) |
|
|
|
|
|
|
|
|
|
|
|
Colorectal cancer: the clinical problem |
|
|
151 | (1) |
|
The molecular genetics of colorectal cancer |
|
|
151 | (4) |
|
Empirical therapies for colorectal cancer |
|
|
155 | (1) |
|
Biochemical modulation: towards a rational treatment strategy for advanced colorectal cancer |
|
|
155 | (1) |
|
Interferon: a novel approach to biochemical modulation of fluoropyrimidines |
|
|
156 | (1) |
|
Interferon regulatory events in 5-fluorouracil treated cells |
|
|
157 | (1) |
|
5-Fluorouracil and interferon: from laboratory to clinic |
|
|
158 | (3) |
|
Future directions for treatment with interferon-containing regimens |
|
|
161 | (8) |
|
13. Melanoma and basal cell carcinoma |
|
|
169 | (16) |
|
|
|
|
|
|
|
|
169 | (1) |
|
Interferons as single agents in the treatment of disseminated melanoma |
|
|
169 | (8) |
|
Treatment of basal cell carcinoma with interferons |
|
|
177 | (8) |
|
|
|
185 | (12) |
|
|
|
|
|
|
|
|
|
|
|
Ovarian cancer: etiology and standard therapy |
|
|
185 | (1) |
|
Current chemotherapy for ovarian cancer |
|
|
186 | (1) |
|
Experimental data for the efficacy of interferons in epithelial ovarian cancer |
|
|
187 | (1) |
|
|
|
188 | (1) |
|
|
|
189 | (4) |
|
|
|
193 | (4) |
|
15. Interferon in urological tumors: bladder cancer |
|
|
197 | (14) |
|
|
|
|
|
|
|
|
|
|
|
General characteristics of bladder cancer |
|
|
197 | (1) |
|
Immunological features of bladder cancer |
|
|
198 | (2) |
|
Clinical therapy of bladder cancer |
|
|
200 | (1) |
|
Clinical use of interferon in bladder cancer |
|
|
201 | (10) |
|
16. Interferon in urological tumors: renal carcinoma |
|
|
211 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
211 | (1) |
|
|
|
212 | (7) |
|
|
|
219 | (1) |
|
|
|
219 | (1) |
|
|
|
220 | (5) |
|
|
|
225 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
225 | (1) |
|
Malignant mesothelioma cells as targets for immune effector cells |
|
|
225 | (3) |
|
Interferon in the treatment of malignant mesothelioma |
|
|
228 | (9) |
|
18. Interferon-alpha in combination with other biological agents |
|
|
237 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
237 | (1) |
|
Retinoids and interferons |
|
|
237 | (4) |
|
Interleukin-2 and interferon |
|
|
241 | (2) |
|
|
|
243 | (12) |
|
19. Antiangiogenic therapy of hemangiomas with interferon-alpha |
|
|
255 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
255 | (1) |
|
Clinical studies of interferon-alpha for the treatment of endangering hemangiomas |
|
|
256 | (2) |
|
Toxicities of interferon-alpha |
|
|
258 | (1) |
|
Current protocol for interferon-alpha therapy |
|
|
259 | (2) |
|
A model of the mechanism for the antiangiogenic property of interferon-alpha |
|
|
261 | (1) |
|
Implications for other diseases treated with interferon-alpha |
|
|
261 | (1) |
|
Antiangiogenic activity of interferon-alpha in comparison to other angiogenesis inhibitors |
|
|
262 | (1) |
|
|
|
262 | (5) |
|
20. Interferon in nonmalignant diseases: scleroderma, keloid, fibrosis |
|
|
267 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
267 | (1) |
|
Fibrosis and wound healing |
|
|
267 | (2) |
|
|
|
269 | (1) |
|
|
|
270 | (5) |
|
21. Treatment of multiple sclerosis with interferon |
|
|
275 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
275 | (1) |
|
Interferon trials in multiple sclerosis |
|
|
276 | (8) |
|
Biological effects of interferons: relationship to efficacy in multiple sclerosis |
|
|
284 | (7) |
|
22. Interferon-gamma in nonmalignant disease |
|
|
291 | (24) |
|
|
|
|
|
|
|
|
|
|
|
|
|
291 | (1) |
|
Physiology of interferon-gamma |
|
|
292 | (2) |
|
Pharmacology of interferon-gamma |
|
|
294 | (1) |
|
Chronic granulomatous disease |
|
|
295 | (1) |
|
Interferon-gamma in the treatment of infections |
|
|
296 | (3) |
|
Interferon-gamma therapy for immunodeficiencies |
|
|
299 | (4) |
|
Interferon-gamma as a vaccine adjuvant |
|
|
303 | (1) |
|
Interferon-gamma in the treatment of autoimmune and inflammatory disorders |
|
|
303 | (3) |
|
|
|
306 | (9) |
|
23. Interferon-gamma in malignant disease |
|
|
315 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
315 | (1) |
|
Structure of interferon-gamma |
|
|
315 | (1) |
|
Function of interferon-gamma |
|
|
315 | (2) |
|
Phase I trials of interferon-gamma |
|
|
317 | (3) |
|
Interferon-gamma in combination therapy |
|
|
320 | (3) |
|
Phase II trials in specific tumors |
|
|
323 | (4) |
|
|
|
327 | (4) |
|
24. Toxicities of interferons |
|
|
331 | (34) |
|
|
|
|
|
|
|
|
331 | (1) |
|
|
|
331 | (3) |
|
|
|
334 | (2) |
|
|
|
336 | (3) |
|
Effects on hormones and lipids |
|
|
339 | (1) |
|
|
|
340 | (1) |
|
|
|
340 | (1) |
|
|
|
341 | (2) |
|
|
|
343 | (1) |
|
Cutaneous and mucosal toxicities |
|
|
343 | (1) |
|
Intestinal disturbance and liver toxicity |
|
|
343 | (1) |
|
|
|
344 | (1) |
|
|
|
344 | (1) |
|
Anti-interferon antibodies |
|
|
345 | (1) |
|
|
|
345 | (1) |
|
Toxicities of combination therapies |
|
|
345 | (3) |
|
Treatment of side effects |
|
|
348 | (1) |
|
|
|
349 | (1) |
|
|
|
349 | (16) |
|
25. Nursing and pharmacy aspects of interferon therapy |
|
|
365 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
365 | (1) |
|
Pretreatment interview and assessment |
|
|
365 | (2) |
|
|
|
367 | (3) |
|
|
|
370 | (2) |
|
Side effects: comments and management |
|
|
372 | (2) |
|
|
|
374 | (1) |
|
|
|
374 | (1) |
|
Appendix 25A: Practical guidelines for outpatient administration of interferon |
|
|
375 | (1) |
|
Appendix 25B: Selected comments of patients in the pilot study on their reactions to interferon therapy |
|
|
375 | (2) |
|
26. The economic aspects of interferon |
|
|
377 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
377 | (2) |
|
Principles of economic evaluation |
|
|
379 | (7) |
|
|
|
386 | (2) |
|
|
|
388 | (3) |
|
27. Systemic administration of interferons for inhibition of cancer metastasis |
|
|
391 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
391 | (1) |
|
The pathogenesis of cancer metastasis |
|
|
391 | (3) |
|
Expression of the angiogenic phenotype in metastatic tumors |
|
|
394 | (1) |
|
Control of angiogenesis by interferons |
|
|
395 | (1) |
|
Control of tumor cell invasion by interferons |
|
|
396 | (2) |
|
Expression of multidrug resistant phenotype by metastatic cells |
|
|
398 | (1) |
|
Interferon therapy of cancer metastasis: future directions |
|
|
399 | (6) |
| Index |
|
405 | |
Shopping Cart
Need Help? eService@ecampus.com
Copyright© 1999-2008
